Rocket Pharmaceuticals, Inc. (RCKT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Rocket Pharmaceuticals highlighted its strategic shift to cardiac gene therapy and said it is currently running three clinical trials in Danon disease, PKP2-related arrhythmogenic cardiomyopathy, and BAG3-related dilated cardiomyopathy. Management also emphasized the earlier CBER approval of KRESLADI for severe LAD-I, marking a key regulatory milestone. The update is mostly strategic and operational, with limited immediate market-moving detail.

Analysis

RCKT’s strategic pivot creates a cleaner story but also a higher bar: the market is no longer valuing a diversified platform, it is underwriting a concentrated readout sequence in three cardiac programs. That concentration can work in its favor if one asset validates the modality, because gene therapy platform multiples tend to re-rate quickly once a single program demonstrates durable cardiac biomarker and clinical signal. The second-order beneficiary is any partner or supplier ecosystem tied to AAV manufacturing and cardiac imaging/biomarker infrastructure, while competitors pursuing broader cardiomyopathy franchises face a tougher funding and differentiation environment if Rocket shows first-mover traction.

The key risk is timeline asymmetry. Near-term catalysts are conference-driven sentiment, but the real value inflection is months away and likely binary around each trial update; in the interim, shares can de-rate on silence, trial design ambiguity, or any signal that enrollment or dose expansion is slower than expected. Because these programs target severe, last-line patients, efficacy expectations are high but tolerability tolerance is low: even modest safety noise can compress the multiple sharply, especially after the company has already shifted identity away from its earlier franchise.

The contrarian view is that the market may be underestimating how much of the “cardiac gene therapy” premium is already embedded in the stock after the strategic repositioning. If the upcoming data are merely consistent rather than clearly superior, the stock could behave like a funded biotech with three shots on goal rather than a category winner. Conversely, if one asset shows cleaner functional improvement than expected, the move could be outsized because shorts likely anchor to the company’s earlier mixed execution rather than to the new cardio-focused setup.

Key Decisions for Investors

• Long RCKT into the next clinical-data window only, sized as a catalyst trade rather than a core position; target 15-25% upside on a positive readout versus 20%+ downside if safety/efficacy disappoints.
• If already long, monetize strength into conference-driven rallies and keep a residual position for the binary clinical update; use a trailing stop around 10-12% below post-rally highs to protect against low-liquidity biotech giveback.
• For higher-conviction expression, buy RCKT call spreads 3-6 months out to capture trial timing while limiting theta bleed; this fits a 2:1 to 3:1 payoff if data are positive.
• Pair trade: long a diversified cardiovascular large-cap biotech/healthcare basket versus short RCKT if the stock rallies on narrative but before data de-risks; this hedges sector beta while isolating execution risk.
• Watch for a competitor basket reaction in other cardiac gene therapy names and AAV tooling suppliers; if RCKT validates the space, use strength in peers to fade the lowest-quality names with the most stretched expectations.